In vivo anti-angiogenic effects further support the promise of the antineoplasic activity of methyl jasmonate

• Autor(a) principal: Pereira Lopes, Jef.
• Data de Publicação: 2010
• Outros Autores: Barbosa, Mr., Stella, Cn., Santos, Wa., Pereira, Em., Nogueira-neto, J., Augusto, Em., Silva, Lv., Smaili, Soraya Soubhi [UNIFESP], Gomes, Lf.
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UNIFESP
• Texto Completo: http://dx.doi.org/10.1590/S1519-69842010000200029; http://repositorio.unifesp.br/handle/11600/5711
• topic: methyl jasmonate; antiangiogenesis; CAM model; endothelial cell culture; HUVEC; metiljasmonato; antiangiogênese; modelo da CAM; cultura de células endoteliais; HUVEC

Molecular plant components have long been aimed at the angiogenesis and anti-angiogenesis pathways, and have been tested as sources for antineoplasic drugs with promising success. The present work deals with the anti-angiogenic effects of Methyl Jasmonate. Jasmonate derivatives were demonstrated to selectively damage the mitochondria of cancer cells. In vitro, 1-10 mM Methyl Jasmonate induced the cell death of the human umbilical vein endothelial cells (HUVEC) and the Murine melanoma cells (B16F10), while micromolar concentrations were ineffective. In vivo, comparable concentrations were toxic and reduced the vessel density of the Chorioallantoic Membrane of the Chicken Embryo (CAM). However, 1-10 µM concentrations produced a complex effect. There was increased capillary budding, but the new vessels were leakier and less organised than corresponding controls. It is suggested that not only direct toxicity, but also the drug effects upon angiogenesis are relevant to the antineoplasic effects of Methyl Jasmonate.